



Authorisations and safety of veterinary medicinal products 2025

Credits

Publisher

Swissmedic, Swiss Agency for Therapeutic Products
Medicinal Product Authorisation and Vigilance Sector
Veterinary Medicines Division
Hallerstrasse 7
3012 Bern
Switzerland
www.swissmedic.ch

Editors

Cedric Müntener, Veterinary Assessor
Nina Walser, Head of Division
Isabelle Zaugg, Head of Unit
Alexandre Scherer, Regulatory Manager

Layout and typesetting

Swissmedic, Communication Division

Contents

1	Newly authorised veterinary medicinal products	4
2	Extensions	6
3	Number of authorised veterinary medicinal products 2023 to 2025	9
4	Safety of veterinary medicinal products	10

1 Newly authorised veterinary medicinal products

In total, 22 new veterinary medicinal products were authorised during 2025.

New active substances	7
Known active substances with innovation	3
Known active substances without innovation	12
New authorisation applications withdrawn	2
New authorisation applications rejected	0

The following veterinary medicinal products were authorised:

New active substances

Special procedure	Authorisation number	Name	Indication	Target animal species*
None	69494	Protivity ad us. vet., lyophilisate and solvent for suspension for injection for cattle	Attenuated live vaccine against <i>M. bovis</i> in cattle	
None	69764	Poulvac Procerta HVT-IBD ad us. vet., concentrate and solvent for suspension for injection for chickens	Live vaccine for active immunisation of day-old chicks and embryonated chicken eggs against Marek's disease and the infectious bursitis virus	
None	69812	Zenrelia ad us. vet., film-coated tablets for dogs	Dermatological product for dogs	
None	69876	BTVPUR ad us. vet., injectable suspension for sheep and cattle	Inactivated vaccine for active immunisation of cattle and sheep against blue tongue disease	 
None	69902	Tessie 0.3 mg/mL ad us. vet., oral solution for dogs	For short-term relief of situational anxiety and fear in dogs	
None	70046	Numelvi ad us. vet., tablets for dogs	Dermatological product for dogs	
Temporary authorisation	70251	BULTAVO 3 ad us. vet., suspension for injection for sheep and cattle	To stimulate active immunity against blue tongue virus in vaccinated animals (sheep and cattle)	 



*Source of animal pictograms: Commission Implementing Regulation (EU) 2024/875 of 21 March 2024 adopting a list of abbreviations and pictograms common throughout the Union to be used on the packaging of veterinary medicinal products for the purposes of Article 10(2) and Article 11(3) of Regulation (EU) 2019/6 of the European Parliament and of the Council

Available at: http://data.europa.eu/eli/reg_impl/2024/875/oj. Colour has been changed from black (original) to brown.

Known active substances with innovation


Special procedure	Authorisation number	Name	Indication	Target animal species*
None	69702	Apelka 5 mg/mL ad us. vet., oral solution for cats	To stabilise hyperthyroidism in cats prior to surgical thyroidectomy and for the long-term treatment of feline hyperthyroidism	
Under Art. 13 TPA	69802	Bravecto injectable ad us. vet., powder and solvent for suspension for injection for dogs	To treat tick and flea infestations in dogs	
Under Art. 13 TPA	69937	Trilotab ad us. vet., chewable tablets for dogs	For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing's syndrome) in dogs	

Known active substances without innovation

Special procedure	Authorisation number	Name	Indication	Target animal species*
Under Art. 13 TPA	69284	Doramax 5 mg/mL Pour-on ad us. vet., pour-on solution for cattle	To prevent and treat endoparasites and ectoparasites in cattle	
None	69480	Prednisolon Streuli ad us. vet., divisible tablets for dogs and cats	Corticosteroid for dogs and cats	
None	69528	Milpro Chewy Hund ad us. vet., chewable tablets	Broad-spectrum anthelmintic, prevention of heartworm disease, for dogs	
Under Art. 13 TPA	69544	Doramax 10 mg/mL ad us. vet., solution for injection for cattle, sheep and pigs	Antiparasitic for cattle, sheep and pigs	
None	69653	Ketabel 100 mg/mL ad us. vet., solution for injection for animals	General anaesthetic for animals	All animal species
None	69768	Vominil 10 mg/mL ad us. vet., solution for injection for dogs and cats	Antiemetic for dogs and cats	
Under Art. 13 TPA	69770	Doramec 10 mg/mL ad us. vet., solution for injection for cattle, sheep and pigs	Broad-spectrum antiparasitic for cattle, sheep and pigs	
Under Art. 13 TPA	69893	Alpramil ad us. vet., film-coated tablets for cats	Broad-spectrum anthelmintic, prevention of heartworm disease, for cats	

Special procedure	Authorisation number	Name	Indication	Target animal species*
Under Art. 13 TPA	69894	Alpramil ad us. vet., tablets for dogs	Broad-spectrum anthelmintic, prevention of heartworm disease, for dogs	
None	69942	Bimacure ad us. vet., suspension for intrauterine use, for cattle	Intrauterine treatment of cattle in the case of subacute and chronic endometritis and repeated return to oestrus	
Under Art. 13 TPA	69953	Dexdormostart 0.5 mg/mL ad us. vet., solution for injection for dogs and cats	Sedative and analgesic for dogs and cats	 
Under Art. 13 TPA	70297	Intramar Seal 2.6 g ad us. vet., suspension for intramammary use, for cattle	Antibiotic-free udder protection during the dry period, for cattle (dairy cows)	

Number of newly authorised veterinary medicinal products 2023 – 2025



2 Extensions

14 extensions were authorised in 2025.


New target animal species	0
Indication extension	8
New dosage strength	3
New pharmaceutical form	2
New administration route	1
Extensions withdrawn	1
Extensions rejected	0

The following extensions were authorised:

Extension	Special procedure	Authorisation number	Name	New indications, dosage strengths, pharmaceutical form or administration route
New indication	None	58748	Rifen 10% ad us. vet., solution for injection for cattle, horses and pigs	Inflammatory diseases of the musculoskeletal system in cattle
	None	66740	Stronghold Plus ad us. vet., spot-on solution for cats	Treatment of notoedric mange (<i>Notoedres cati</i>)
	None	65791	NexGard Spectra ad us. vet., chewable tablets for dogs	Can be used as part of the treatment strategy against flea allergy dermatitis (FAD).
	Under Art. 13 TPA	67720	Simparica Trio ad us. vet., chewable tablets for dogs	For the treatment of angiostrongylosis (<i>Angiostrongylus vasorum</i>)
	None	68382	NexGard Combo Spot-on for cats ad us. vet., spot-on solution	For the treatment of ocular worm infestations (<i>Thelazia callipaeda</i>)
	None	69133	Daxcox ad us. vet., flavoured tablets for dogs	For the treatment of pain and inflammation associated with orthopaedic or soft tissue surgery
	Under Art. 13 TPA	67720	Simparica Trio ad us. vet., chewable tablets for dogs	To reduce the risk of infection with <i>Dipylidium caninum</i> via transmission by <i>Ctenocephalides felis</i> for one month after treatment. The risk of infection is reduced indirectly by the effect of the veterinary medicinal product against the vector (<i>C. felis</i>).
	Under Art. 13 TPA	66740	Stronghold Plus ad us. vet., spot-on solution for cats	To reduce the risk of infection with <i>Dipylidium caninum</i> via transmission by <i>Ctenocephalides felis</i> for one month after treatment. The risk of infection is reduced indirectly by the effect of the veterinary medicinal product against the vector (<i>C. felis</i>).


Extension	Special procedure	Authorisation number	Name	New indications, dosage strengths, pharmaceutical form or administration route
New dosage strengths	None	57001	Clavaseptin ad us. vet., divisible tablets for dogs	Dosage strength 750mg
	None	69133	Daxocox ad us. vet., flavoured tablets for dogs	Dosage strengths 140 mg and 200 mg
	Under Art. 13 TPA	70065	Vetoryl ad us. vet., chewable tablets for dogs	Dosage strength 20mg
New pharmaceutical form	Under Art. 13 TPA	70065	Vetoryl ad us. vet., chewable tablets for dogs	Pharmaceutical form "chewable tablets"
	Under Art. 13 TPA	69984	Felimazole 5 mg/mL ad us. vet., oral solution for cats	Pharmaceutical form "oral solution"
New administration route	None	1780	Prevexxion RN+HVT+IBD ad us. vet., concentrate and solution for suspension for injection for chickens	Administration route "in ovo"

Number of extensions 2023 – 2025



3 Number of authorised veterinary medicinal products 2023 to 2025

Number of authorised veterinary medicinal products 2023 – 2025



The number of authorised veterinary medicinal products corresponds to the number of authorisations under a single authorisation number. The authorisation number includes different dosage strengths and pack sizes. Countries count authorisations and issue authorisation numbers in different ways. The figures listed above therefore cannot be compared directly with the number of authorisations in other countries.

4 Safety of veterinary medicinal products

Reports

A total of 722 reports were recorded in 2025:

- 590 reports in small animals (dogs and cats) or pets (incl. exotics)
- 120 reports in livestock (incl. cows/cattle/calves, horses)
- 12 reactions in users

Reporters

- 555 cases were reported by the marketing authorisation holders
- 90 cases were reported by professionals
- 70 cases of animal exposure to veterinary medicinal products were forwarded by Tox Info Suisse
- 7 cases were reported by administrative bodies and owners.

In addition, Tox Info Suisse forwarded 155 cases of human exposure to veterinary medicinal products. These cases are not taken into account in the statistics.

Medicinal product types

The most frequent medicinal product types were:

- Antiparasitics (187)
- Immunological veterinary medicinal products (156)
- Products to modulate the nervous system (115)
- Products containing hormones (92)
- Non-steroidal anti-inflammatory drugs (41)

The number of reports does not allow any direct conclusion to be drawn about the safety of a medicinal product type.

Cases of suspected lack of efficacy

In 2025, 175 cases of suspected lack of efficacy were reported, largely for antiparasitics, products containing hormones, antidiabetics and products to modulate the nervous system.


Signals

30 signals were opened and 12 closed in 2025.

Examples of signals:

- Anorexia, diarrhoea and hypersensitivity reactions following injection of a veterinary medicinal product containing the active substance fluralaner
- Facial paralysis in dogs after use of ear drops containing florfenicol, terbinafine and mometasone
- Eye disorders, hypersensitivity reactions, inner ear disorders and local reactions after use of ear drops containing florfenicol, terbinafine and betamethasone
- Various adjustments for veterinary medicinal products containing monoclonal antibodies for use in dogs and cats with osteoarthritis
- Reactions on self-injection of a vaccine against *B. bronchiseptica* for use in dogs

Number of reports of adverse veterinary drug reactions 2023 to 2025





Schweizerisches Heilmittelinstitut
Institut suisse des produits thérapeutiques
Istituto svizzero per gli agenti terapeutici
Swiss Agency for Therapeutic Products

Swissmedic, Swiss Agency for Therapeutic Products
Medicinal Product Authorisation and Vigilance Sector
Veterinary Medicines Division
Hallerstrasse 7
3012 Bern
Switzerland
www.swissmedic.ch

